tiprankstipranks
Trending News
More News >

NetraMark Unveils AI-Driven Clinical Trial Breakthrough

NetraMark Unveils AI-Driven Clinical Trial Breakthrough

NetraMark Holdings (TSE:AIAI) has released an update.

Confident Investing Starts Here:

NetraMark Holdings is set to revolutionize clinical trials with its new Treatment Attitude Profile (TAP™) scale, unveiled at the ASCP Annual Meeting. The scale, powered by NetraMark’s NetraAI technology, identifies placebo responders, enhancing trial design and patient selection. This innovation promises to reduce time, cost, and failure rates in psychiatric clinical trial development, marking a significant step forward in treatment efficacy discovery.

For further insights into TSE:AIAI stock, check out TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App